EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Perspectives on development and advancement of new tuberculosis vaccines

Christopher da Costa, Christine S Benn, Thomas Nyirenda, Evans Mpabalwani, Harleen M S Grewal, Rizwan Ahmed, Nathan Kapata, Peter S Nyasulu, Markus Maeurer, David S Hui, Delia Goletti, Alimuddin Zumla

International Journal of Infectious Diseases · 2024-04 · 141 · 106987

DOI: 10.1016/j.ijid.2024.106987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Infectious Diseases, 2024-04. Verfasst von Christopher da Costa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harvard T.H. Chan School of Public Health, Department of Global Health and Population, Boston, MA, USA; Coalition for Epidemic Preparedness Innovatio…. Hauptthemen laut MEDLINE: Tuberculosis Vaccines, Tuberculosis, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a leading cause of death worldwide and is estimated to have caused 1.3 million deaths worldwide in 2022. Approximately one quarter of the world's population are infected with Mycobacterium tuberculosis, of whom up to 10% will progress to developing active TB disease. Achieving the World Health Organization End TB Strategy targets of a 95% reduction in TB mortality and a 90% reduction in TB incidence worldwide by 2035 remains a daunting task. The continuing spread of multidrug-resistant TB adds another obstacle to achieving global TB control. Larger funding pledges coupled with technological advances have recently enabled the enhancement of TB vaccine development efforts. These are yielding a pipeline of over 17 products currently in different stages of clinical trials. Emerging promising phase I and II trial results and advancement to phase III trials have necessitated "vaccine preparedness" in parallel so that a smooth transition from any positive clinical trial result to phase IV evaluation and implementation into policy and practice can follow. Promotion of a human rights-based approach, which recognizes and upholds the fundamental rights of all affected by the disease, is essential to ensure universal access to quality TB vaccines, regardless of their background or personal circumstances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis VaccinesTuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansWorld Health Organization

Stichwörter der Autor:innen

AdvocacyBCGImmunityPreventionTuberculosisVaccines

Substanzen

Tuberculosis Vaccines

Autor:innen und Institutionen

  • Harvard T.H. Chan School of Public Health, Department of Global Health and Population, Boston, MA, USA; Coalition for Epidemic Preparedness Innovations, Research and Development Division, Washington, DC, USA. Electronic…
  • Bandim Health Project, University of Southern Denmark, Department of Clinical Research and Danish Institute for Advanced Study, Odense, Denmark.
  • European Developing Countries Clinical Trials partnership (EDCTP) Africa Office, Cape Town, South Africa.
  • University Teaching Hospital, University of Zambia School of Medicine, Department of Paediatrics and Child Health, Lusaka, Zambia.
  • University of Bergen, Department of Clinical Science, Bergen Integrated Diagnostic Stewardship Cluster, Bergen, Norway.
  • Department of Respiratory Medicine, Royal Bolton Hospital, and University of Bolton, Farnworth, Bolton, UK.

Zitieren

APA

da Costa, C., Benn, C. S., Nyirenda, T., Mpabalwani, E., Grewal, H. M. S., Ahmed, R., Kapata, N., Nyasulu, P. S., Maeurer, M., Hui, D. S., Goletti, D., & Zumla, A. (2024). Perspectives on development and advancement of new tuberculosis vaccines. International Journal of Infectious Diseases, 141, 106987. https://doi.org/10.1016/j.ijid.2024.106987

Vancouver

da Costa C, Benn CS, Nyirenda T, Mpabalwani E, Grewal HMS, Ahmed R, et al. Perspectives on development and advancement of new tuberculosis vaccines. International Journal of Infectious Diseases. 2024;141:106987. doi:10.1016/j.ijid.2024.106987

BibTeX
@article{daCosta2024,
  author = {da Costa, Christopher and Benn, Christine S and Nyirenda, Thomas and Mpabalwani, Evans and Grewal, Harleen M S and Ahmed, Rizwan and Kapata, Nathan and Nyasulu, Peter S and Maeurer, Markus and Hui, David S and Goletti, Delia and Zumla, Alimuddin},
  title = {Perspectives on development and advancement of new tuberculosis vaccines},
  journal = {International Journal of Infectious Diseases},
  year = {2024},
  volume = {141},
  pages = {106987},
  doi = {10.1016/j.ijid.2024.106987}
}
Kostenlos starten →